SyStemix gene/cell therapy news

STMX said it is restructuring to focus on clinical programs, and will delay longer term, unspecified projects. The company's goal is to reduce its 1996 net burn rate by 20-25 percent compared to 1995 by reducing its 282 person staff by about 10 percent as well as through partnering. The company expects to burn $48 million in 1995. At Sept. 30, STMX had $71.6 million in cash.

Preliminary results from STMX's Phase I/II trial using self-renewing, pluripotent hematopoietic stem cells to support multiple myeloma patients following chemotherapy, show that stem cell transplants can engraft in 12 days for neutrophils, and 18 days for platelets. More details will be released at the American Society of Hematology meeting in Seattle this week. ...